THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE

Aim. To study the possibility of enhancing the antianginal effect of long-acting nitrates by their combination with trimetazidine in patients with stable angina. Material and methods. Patients with ischemic heart disease (IHD, stable angina; n=55) were included into the study. Patients were randomiz...

Full description

Bibliographic Details
Main Authors: L. E. Chekuldaeva, S. V. Obuhova, A. A. Simakov, L. V. Poljaeva, E. I. Rjazanova
Format: Article
Language:English
Published: Столичная издательская компания 2015-12-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/489
_version_ 1797232392276017152
author L. E. Chekuldaeva
S. V. Obuhova
A. A. Simakov
L. V. Poljaeva
E. I. Rjazanova
author_facet L. E. Chekuldaeva
S. V. Obuhova
A. A. Simakov
L. V. Poljaeva
E. I. Rjazanova
author_sort L. E. Chekuldaeva
collection DOAJ
description Aim. To study the possibility of enhancing the antianginal effect of long-acting nitrates by their combination with trimetazidine in patients with stable angina. Material and methods. Patients with ischemic heart disease (IHD, stable angina; n=55) were included into the study. Patients were randomized to receive trimetazidine 35 mg 2 times a day (intervention group) or placebo (control group) in addition to standard therapy. A daily number of angina attacks, amount of short-acting nitroglycerin tablets consumed per week, exercise tolerance by the bicycle ergometry with the calculation of the threshold power and the work capacity were assessed at baseline and after 2 months of the drugs taking, as well as 2 months after the drugs withdrawal. Results. Significant reduction in nitroglycerin tablets consumption (1 month — by 61.8%, after 2 months — 72.5%, p<0.05) were found in the intervention group compared with the control group. Low intake of nitroglycerin compared with baseline (p<0.05) was maintained for 2 months after discontinuation of study drug. Significant increase in the threshold power (1 month — by 32.3%, after 2 months — 37.5%, p<0.05) was observed in the intervention group compared to baseline and with the control group. Conclusion. Trimetazidine in the treatment of stable angina has high clinical efficacy.
first_indexed 2024-03-08T14:05:12Z
format Article
id doaj.art-a474de78d118444dbfbd8803a0b815b9
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-04-24T15:59:33Z
publishDate 2015-12-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-a474de78d118444dbfbd8803a0b815b92024-04-01T07:43:26ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-12-018451552010.20996/1819-6446-2012-8-4-515-520489THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASEL. E. Chekuldaeva0S. V. Obuhova1A. A. Simakov2L. V. Poljaeva3E. I. Rjazanova4Medical Care Unit №2, SamaraMedical Care Unit №2, SamaraSamara Medical Institute "Reaviz"Medical Care Unit №2, SamaraMedical Care Unit №2, SamaraAim. To study the possibility of enhancing the antianginal effect of long-acting nitrates by their combination with trimetazidine in patients with stable angina. Material and methods. Patients with ischemic heart disease (IHD, stable angina; n=55) were included into the study. Patients were randomized to receive trimetazidine 35 mg 2 times a day (intervention group) or placebo (control group) in addition to standard therapy. A daily number of angina attacks, amount of short-acting nitroglycerin tablets consumed per week, exercise tolerance by the bicycle ergometry with the calculation of the threshold power and the work capacity were assessed at baseline and after 2 months of the drugs taking, as well as 2 months after the drugs withdrawal. Results. Significant reduction in nitroglycerin tablets consumption (1 month — by 61.8%, after 2 months — 72.5%, p<0.05) were found in the intervention group compared with the control group. Low intake of nitroglycerin compared with baseline (p<0.05) was maintained for 2 months after discontinuation of study drug. Significant increase in the threshold power (1 month — by 32.3%, after 2 months — 37.5%, p<0.05) was observed in the intervention group compared to baseline and with the control group. Conclusion. Trimetazidine in the treatment of stable angina has high clinical efficacy.https://www.rpcardio.online/jour/article/view/489anginaischemic heart diseasetrimetazidinegenerics
spellingShingle L. E. Chekuldaeva
S. V. Obuhova
A. A. Simakov
L. V. Poljaeva
E. I. Rjazanova
THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
Рациональная фармакотерапия в кардиологии
angina
ischemic heart disease
trimetazidine
generics
title THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
title_full THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
title_fullStr THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
title_full_unstemmed THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
title_short THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
title_sort problem of interchangeability of drug products trimetazidine is an effective treatment of patients with ischemic heart disease
topic angina
ischemic heart disease
trimetazidine
generics
url https://www.rpcardio.online/jour/article/view/489
work_keys_str_mv AT lechekuldaeva theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT svobuhova theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT aasimakov theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT lvpoljaeva theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT eirjazanova theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT lechekuldaeva problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT svobuhova problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT aasimakov problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT lvpoljaeva problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease
AT eirjazanova problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease